Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CBX7 | O95931 | 1/20 | 0.48 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.48 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.48 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909232 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1L3MBTL1L3MBTL3ACHE | |
| SCHEMBL311608 | 0.81 | L3MBTL1 (0.59) | ALDH1A1L3MBTL1LMNAALOX15TSHR | |
| SCHEMBL30070239 | 0.81 | L3MBTL1 (0.59) | ALDH1A1L3MBTL1LMNAALOX15TSHR | |
| SCHEMBL27991280 | 0.80 | L3MBTL3 (0.58) | KDM4EALDH1A1L3MBTL1L3MBTL3ACHE | |
| SCHEMBL21567932 | 0.79 | KDM4E (0.48) | KDM4EALDH1A1L3MBTL1L3MBTL3ACHE | |
| SCHEMBL22030869 | 0.79 | KDM4E (0.61) | KDM4EALDH1A1L3MBTL1L3MBTL3ACHE | |
| SCHEMBL4315788 | 0.78 | L3MBTL3 (0.57) | KDM4EALDH1A1L3MBTL1L3MBTL3ACHE | |
| SCHEMBL18909245 | 0.78 | L3MBTL3 (0.54) | KDM4EALDH1A1L3MBTL1L3MBTL3ACHE | |
| SCHEMBL15759106 | 0.78 | GNAI3 (0.50) | KDM4EALDH1A1L3MBTL1L3MBTL3ACHE | |
| SCHEMBL5779438 | 0.77 | L3MBTL3 (0.55) | KDM4EALDH1A1L3MBTL1L3MBTL3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-3416967-B1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-02-09 | — | — | EP | disclosed |
| EP-3416967-B1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-02-09 | — | — | EP | disclosed |
| CN-108473501-B | Therapeutic compounds, compositions and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| EP-3416967-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-20180354959-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-12-13 | — | — | US | disclosed |
| WO-2017140825-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140825-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | KDM4E 1725/4885ALDH1A1 1817/4885L3MBTL1 3821/4885 |
| US-20180354959-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | KDM4E 2100/4885ALDH1A1 1804/4885L3MBTL1 4006/4885 |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | KDM4E 1725/4885ALDH1A1 1817/4885L3MBTL1 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.